Suchergebnisse - "Uldrick, Thomas S"

PubPharm (7)

1

Remission after rituximab for HHV8+ MCD : what next?

enthalten in: Blood advances | 2023

von Ramaswami, R. | Uldrick, T.

CommentOn: Blood Adv. 2023 Sep 26;7(18):5663-5669. - PMID 37288720

2

International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease

enthalten in: Blood advances | 2020

von van Rhee, F. | Oksenhendler, E. | Srkalovic, G. | +26

3

Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate

enthalten in: Blood | 2020

von Lurain, K. | Uldrick, T. | Ramaswami, R. | +14

4

Treatment of Kaposi Sarcoma Herpesvirus-Associated Multicentric Castleman Disease

enthalten in: Hematology/oncology clinics of North America | 2018

von Lurain, K. | Yarchoan, R. | Uldrick, T.

5

Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease

enthalten in: Blood | 2014

von Uldrick, T. | Polizzotto, M. | Aleman, K. | +9

6

Treatment outcomes in AIDS-related diffuse large B-cell lymphoma in the setting roll out of combination antiretroviral therapy in South Africa

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2013

von de Witt, P. | Maartens, D. | Uldrick, T. | +1

7

Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease

enthalten in: Current opinion in oncology | 2012

von Uldrick, T. | Polizzotto, M. | Yarchoan, R.

1
[1]